Ptc Therapeutics (PTCT) Total Liabilities (2012 - 2026)

Ptc Therapeutics' Total Liabilities history runs 15 years deep, the most recent figure standing at $3.4 billion for Q2 2026.

• In Q2 2026, Total Liabilities rose 20.25% year-over-year to $3.4 billion; the TTM figure through Jun 2026 stood at $3.4 billion (up 20.25% YoY), while the FY2025 annual figure was $3.1 billion, up 10.74% from the prior year.
• Total Liabilities for Q2 2026 stood at $3.4 billion, up from $3.0 billion in the prior quarter.
• The five-year high for Total Liabilities was $3.4 billion in Q2 2026, with the low at $1.8 billion in Q3 2022.
• The 5-year median for Total Liabilities is $2.8 billion (2023), against an average of $2.5 billion.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities retreated 5.21% in 2022, then jumped 51.07% in 2024.
• Ptc Therapeutics' Total Liabilities stood at $2.1 billion in 2022, then surged by 32.23% to $2.7 billion in 2023, then rose by 3.27% to $2.8 billion in 2024, then gained by 10.74% to $3.1 billion in 2025, then climbed by 10.04% to $3.4 billion in 2026.
• Business Quant data shows PTCT's Total Liabilities at $3.4 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.1 billion in Q4 2025.